{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:24:20Z","timestamp":1789863860262,"version":"4.0.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"University of Sydney Postgraduate Scholarship"},{"name":"National Health and Medical Research Council-Australian","award":["1197439"],"award-info":[{"award-number":["1197439"]}]},{"name":"National Heart Foundation Future Leader Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Psychiatry Rep"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s11920-024-01564-7","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T08:41:17Z","timestamp":1732869677000},"page":"712-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Using Cannabis and CBD to Sleep: An Updated Review"],"prefix":"10.1007","volume":"26","author":[{"given":"Isobel","family":"Lavender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Garden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald R.","family":"Grunstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon J.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla M.","family":"Hoyos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"1564_CR1","doi-asserted-by":"publisher","first-page":"101588","DOI":"10.1016\/j.ssmph.2023.101588","volume":"25","author":"M Du","year":"2024","unstructured":"Du M, Liu M, Wang Y, Qin C, Liu J. Global burden of sleep disturbances among older adults and the disparities by geographical regions and pandemic periods. SSM - Population Health. 2024;25:101588.","journal-title":"SSM - Population Health"},{"key":"1564_CR2","doi-asserted-by":"crossref","unstructured":"Streatfeild J, Smith J, Mansfield D, Pezzullo L, Hillman D. The social and economic cost of sleep disorders. Sleep. 2021;44(11).","DOI":"10.1093\/sleep\/zsab132"},{"key":"1564_CR3","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3389\/fnmol.2020.00125","volume":"13","author":"AJ Kesner","year":"2020","unstructured":"Kesner AJ, Lovinger DM. Cannabinoids, Endocannabinoids and Sleep. Front Mol Neurosci. 2020;13:125.","journal-title":"Front Mol Neurosci"},{"key":"1564_CR4","doi-asserted-by":"crossref","unstructured":"Kaul M, Zee PC, Sahni AS. Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders. Neurotherapeutics. 2021.","DOI":"10.1007\/s13311-021-01013-w"},{"issue":"6","key":"1564_CR5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1016\/j.pnpbp.2008.04.008","volume":"32","author":"E Murillo-Rodriguez","year":"2008","unstructured":"Murillo-Rodriguez E. The role of the CB1 receptor in the regulation of sleep. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(6):1420\u20137.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"1564_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11920-017-0775-9","volume":"19","author":"KA Babson","year":"2017","unstructured":"Babson KA, Sottile J, Morabito D. Cannabis, Cannabinoids, and Sleep: a Review of the Literature. Curr Psychiatry Rep. 2017;19(4):23.","journal-title":"Curr Psychiatry Rep"},{"issue":"12","key":"1564_CR7","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40263-020-00773-x","volume":"34","author":"C Bhagavan","year":"2020","unstructured":"Bhagavan C, Kung S, Doppen M, John M, Vakalalabure I, Oldfield K, et al. Cannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis. CNS Drugs. 2020;34(12):1217\u201328.","journal-title":"CNS Drugs"},{"key":"1564_CR8","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.smrv.2020.101339","volume":"53","author":"AS Suraev","year":"2020","unstructured":"Suraev AS, Marshall NS, Vandrey R, McCartney D, Benson MJ, McGregor IS, et al. Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Med Rev. 2020;53:101339.","journal-title":"Sleep Med Rev"},{"issue":"6","key":"1564_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.smrv.2014.02.005","volume":"18","author":"PJ Gates","year":"2014","unstructured":"Gates PJ, Albertella L, Copeland J. The effects of cannabinoid administration on sleep: a systematic review of human studies. Sleep Med Rev. 2014;18(6):477\u201387.","journal-title":"Sleep Med Rev"},{"issue":"4","key":"1564_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1037\/pha0000285","volume":"27","author":"N Kuhathasan","year":"2019","unstructured":"Kuhathasan N, Dufort A, MacKillop J, Gottschalk R, Minuzzi L, Frey BN. The use of cannabinoids for sleep: A critical review on clinical trials. Exp Clin Psychopharmacol. 2019;27(4):383\u2013401.","journal-title":"Exp Clin Psychopharmacol"},{"issue":"2","key":"1564_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.chest.2022.04.151","volume":"162","author":"I Lavender","year":"2022","unstructured":"Lavender I, McGregor IS, Suraev A, Grunstein RR, Hoyos CM. Cannabinoids, Insomnia, and Other Sleep Disorders. Chest. 2022;162(2):452\u201365.","journal-title":"Chest"},{"key":"1564_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2147\/NSS.S340949","volume":"14","author":"KJ Maddison","year":"2022","unstructured":"Maddison KJ, Kosky C, Walsh JH. Is There a Place for Medicinal Cannabis in Treating Patients with Sleep Disorders? What We Know so Far. Nat Sci Sleep. 2022;14:957\u201368.","journal-title":"Nat Sci Sleep"},{"issue":"1","key":"1564_CR13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s13311-021-01013-w","volume":"18","author":"M Kaul","year":"2021","unstructured":"Kaul M, Zee PC, Sahni AS. Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders. Neurotherapeutics. 2021;18(1):217\u201327.","journal-title":"Neurotherapeutics"},{"key":"1564_CR14","unstructured":"Long A. MJBiz Factbook: Marijuana industry will add $112.4 billion to US economy in 2024 MJBizDaily: MJBizDaily; 2024 [Available from: https:\/\/mjbizdaily.com\/marijuana-industry-will-add-112-4-billion-to-us-economy-in-2024-mjbiz-factbook\/"},{"issue":"2","key":"1564_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/2049463720922884","volume":"14","author":"SP Alexander","year":"2020","unstructured":"Alexander SP. Barriers to the wider adoption of medicinal Cannabis. Br J Pain. 2020;14(2):122\u201332.","journal-title":"Br J Pain"},{"issue":"2","key":"1564_CR16","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/00207454.2020.1730832","volume":"130","author":"SG Meuth","year":"2020","unstructured":"Meuth SG, Henze T, Essner U, Trompke C, Vila SC. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial. Int J Neurosci. 2020;130(2):1199\u2013205.","journal-title":"Int J Neurosci"},{"key":"1564_CR17","doi-asserted-by":"crossref","unstructured":"Campbell F, Tramer M, Carroll D, Reynolds J, Moore A, McQuay H. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001;325.","DOI":"10.1136\/bmj.323.7303.13"},{"issue":"11","key":"1564_CR18","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.annonc.2020.07.020","volume":"31","author":"P Grimison","year":"2020","unstructured":"Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, et al. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol. 2020;31(11):1553\u201360.","journal-title":"Ann Oncol"},{"issue":"2","key":"1564_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1080\/09540260902782810","volume":"21","author":"TC Kirkham","year":"2009","unstructured":"Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry. 2009;21(2):163\u201371.","journal-title":"Int Rev Psychiatry"},{"issue":"7","key":"1564_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"HC Lu","year":"2016","unstructured":"Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biol Psychiat. 2016;79(7):516\u201325.","journal-title":"Biol Psychiat"},{"issue":"11","key":"1564_CR21","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1007\/BF01922823","volume":"29","author":"M Perez-Reyes","year":"1973","unstructured":"Perez-Reyes M, Timmons MC, Davis KH, Wall EM. A comparison of the pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol. Experientia. 1973;29(11):1368\u20139.","journal-title":"Experientia"},{"key":"1564_CR22","doi-asserted-by":"crossref","unstructured":"Corroon J. Cannabinol and Sleep: Separating Fact from Fiction. Cannabis and Cannabinoid Research. 2021.","DOI":"10.1089\/can.2021.0006"},{"key":"1564_CR23","doi-asserted-by":"publisher","first-page":"108680","DOI":"10.1016\/j.neuropharm.2021.108680","volume":"196","author":"R Spanagel","year":"2021","unstructured":"Spanagel R, Bilbao A. Approved cannabinoids for medical purposes \u2013 Comparative systematic review and meta-analysis for sleep and appetite. Neuropharmacology. 2021;196:108680.","journal-title":"Neuropharmacology"},{"key":"1564_CR24","unstructured":"Australian Government DoH, Therapeutic Goods Administration. . Guidance on quality requirements for medicinal cannabis products; Conforming with Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017 - including 2022 Amendments 2022."},{"issue":"9","key":"1564_CR25","doi-asserted-by":"publisher","first-page":"097001","DOI":"10.1289\/EHP11206","volume":"130","author":"LE Jameson","year":"2022","unstructured":"Jameson LE, Conrow KD, Pinkhasova DV, Boulanger HL, Ha H, Jourabchian N, et al. Comparison of State-Level Regulations for Cannabis Contaminants and Implications for Public Health. Environ Health Perspect. 2022;130(9):097001.","journal-title":"Environ Health Perspect"},{"issue":"1","key":"1564_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s42238-024-00220-4","volume":"6","author":"MM Geweda","year":"2024","unstructured":"Geweda MM, Majumdar CG, Moore MN, Elhendawy MA, Radwan MM, Chandra S, ElSohly MA. Evaluation of dispensaries\u2019 cannabis flowers for accuracy of labeling of cannabinoids content. Journal of Cannabis Research. 2024;6(1):11.","journal-title":"Journal of Cannabis Research"},{"key":"1564_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neubiorev.2021.01.003","volume":"126","author":"D McCartney","year":"2021","unstructured":"McCartney D, Arkell TR, Irwin C, McGregor IS. Determining the magnitude and duration of acute Delta(9)-tetrahydrocannabinol (Delta(9)-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. Neurosci Biobehav Rev. 2021;126:175\u201393.","journal-title":"Neurosci Biobehav Rev"},{"key":"1564_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2017.03.009","volume":"177","author":"JY Park","year":"2017","unstructured":"Park JY, Wu LT. Prevalence, reasons, perceived effects, and correlates of medical marijuana use: A review. Drug Alcohol Depend. 2017;177:1\u201313.","journal-title":"Drug Alcohol Depend"},{"key":"1564_CR29","doi-asserted-by":"publisher","first-page":"885655","DOI":"10.3389\/fphar.2022.885655","volume":"13","author":"SL MacPhail","year":"2022","unstructured":"MacPhail SL, Bedoya-P\u00e9rez MA, Cohen R, Kotsirilos V, McGregor IS, Cairns EA. Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years. Front Pharmacol. 2022;13:885655.","journal-title":"Front Pharmacol"},{"key":"1564_CR30","unstructured":"Medicinal Cannabis Authorised Prescriber Scheme Approvals Australian Therapeutic Goods Administrator2024 [Available from: https:\/\/dashboard-data.health.gov.au\/single\/?appid=f330a1c6-d805-4c64-a6ef-76a69d32d8b7&sheet=4c57fba1-4b0d-423f-a42e-558bd76d4f21&select=clearall."},{"issue":"1","key":"1564_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12954-020-00377-0","volume":"17","author":"N Lintzeris","year":"2020","unstructured":"Lintzeris N, Mills L, Suraev A, Bravo M, Arkell T, Arnold JC, et al. Medical cannabis use in the Australian community following introduction of legal access: the 2018\u20132019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduct J. 2020;17(1):37.","journal-title":"Harm Reduct J"},{"key":"1564_CR32","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/NSS.S390583","volume":"15","author":"A Suraev","year":"2023","unstructured":"Suraev A, Mills L, Abelev SV, Arkell TR, Lintzeris N, McGregor IS. Medical Cannabis Use Patterns for Sleep Disorders in Australia: Results of the Cross-Sectional CAMS-20 Survey. Nat Sci Sleep. 2023;15:245\u201355.","journal-title":"Nat Sci Sleep"},{"issue":"1","key":"1564_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-022-00666-w","volume":"19","author":"N Lintzeris","year":"2022","unstructured":"Lintzeris N, Mills L, Abelev SV, Suraev A, Arnold JC, McGregor IS. Medical cannabis use in Australia: consumer experiences from the online cannabis as medicine survey 2020 (CAMS-20). Harm Reduct J. 2022;19(1):88.","journal-title":"Harm Reduct J"},{"issue":"1","key":"1564_CR34","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12875-022-01946-x","volume":"23","author":"Z Bawa","year":"2022","unstructured":"Bawa Z, McCartney D, Manocha R, McGregor IS. Knowledge, experiences, and attitudes of Australian General Practitioners towards medicinal cannabis: a 2021\u20132022 survey. BMC Primary Care. 2022;23(1):330.","journal-title":"BMC Primary Care"},{"key":"1564_CR35","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","volume":"49","author":"CA MacCallum","year":"2018","unstructured":"MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12\u20139.","journal-title":"Eur J Intern Med"},{"key":"1564_CR36","doi-asserted-by":"crossref","unstructured":"Narayan AJ, Downey LA, Rose S, Di Natale L, Hayley AC. Cannabidiol for moderate-severe insomnia: a randomized controlled pilot trial of 150 mg of nightly dosing. J Clin Sleep Med. 2024.","DOI":"10.5664\/jcsm.10998"},{"key":"1564_CR37","doi-asserted-by":"crossref","unstructured":"Hoyos C, Marshall N, Gordon C, Yee B, McGregor I, Grunstein RR. 0394 The CANnabidiol Use for RElief of Short-Term Insomnia (CAN-REST). a Randomised Placebo-Controlled Clinical Trial. Sleep. 2024;47(Supplement_1):A169-A70.","DOI":"10.1093\/sleep\/zsae067.0394"},{"key":"1564_CR38","doi-asserted-by":"crossref","unstructured":"Suraev A, McGregor I, Marshall N, D'Rozario A, Kao C, Gordon C, et al. O006 Acute effects of combined cannabidiol (CBD) and \u22069-tetrahydrocannabinol (THC) in insomnia disorder: A randomised, placebo-controlled trial using high-density EEG. SLEEP Advances. 2022;3(Supplement_1):A3-A4.","DOI":"10.1093\/sleepadvances\/zpac029.005"},{"key":"1564_CR39","doi-asserted-by":"crossref","unstructured":"Wang M, Faust M, Abbott S, Patel V, Chang E, Clark JI, et al. A Cannabidiol\/Terpene Formulation That Increases Restorative Sleep in Insomniacs: A Double-Blind, Placebo-controlled, Randomized, Crossover Pilot Study. medRxiv. 2023:2023.06.03.23290932.","DOI":"10.1101\/2023.06.03.23290932"},{"key":"1564_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02640414.2020.1797448","volume":"38","author":"D Miller","year":"2020","unstructured":"Miller D, Lastella M, Scanlan A, Bellenger C, Halson S, Roach G, Sargent C. A validation study of the WHOOP strap against polysomnography to assess sleep. J Sports Sci. 2020;38:1\u20136.","journal-title":"J Sports Sci"},{"issue":"3","key":"1564_CR41","doi-asserted-by":"publisher","first-page":"e13793","DOI":"10.1111\/jsr.13793","volume":"32","author":"K Ried","year":"2023","unstructured":"Ried K, Tamanna T, Matthews S, Sali A. Medicinal cannabis improves sleep in adults with insomnia: a randomised double-blind placebo-controlled crossover study. J Sleep Res. 2023;32(3):e13793.","journal-title":"J Sleep Res"},{"key":"1564_CR42","unstructured":"Lavender I, Marshall N, McGregor I, Grunstein R, Yee B, Hoyos C. LBA 1297 A Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Crossover, Pilot Study Investigating the Effects of Cannabinol (CBN) 30 mg and 300 mg on Sleep Architecture and Next-Day Function in Insomnia Disorder (\u2018CUPID\u2019 study). In: Medicine AAoS, editor. SLEEP 2024; Houston, Texas. Frontage Rd., Darien, IL 60561 sleepmeeting.org2024."},{"key":"1564_CR43","doi-asserted-by":"crossref","unstructured":"Walsh JH, Maddison KJ, Rankin T, Murray K, McArdle N, Ree MJ, et al. Treating Insomnia Symptoms with Medicinal Cannabis: A Randomized, Cross-Over Trial of the Efficacy of a Cannabinoid Medicine Compared with Placebo. Sleep. 2021.","DOI":"10.1093\/sleep\/zsab149"},{"issue":"1","key":"1564_CR44","first-page":"1","volume":"43","author":"JL Saleska","year":"2024","unstructured":"Saleska JL, Bryant C, Kolobaric A, D\u2019Adamo CR, Colwell CS, Loewy D, et al. The Safety and Comparative Effectiveness of Non-Psychoactive Cannabinoid Formulations for the Improvement of Sleep: A Double-Blinded, Randomized Controlled Trial. J Am Nutr Assoc. 2024;43(1):1\u201311.","journal-title":"J Am Nutr Assoc"},{"key":"1564_CR45","doi-asserted-by":"crossref","unstructured":"Bonn-Miller MO, Feldner MT, Bynion TM, Eglit GML, Brunstetter M, Kalaba M, et al. A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality. Exp Clin Psychopharmacol. 2023.","DOI":"10.1037\/pha0000682"},{"key":"1564_CR46","doi-asserted-by":"crossref","unstructured":"Kolobaric A, Saleska J, Hewlings SJ, Bryant C, Colwell CS, D\u2019Adamo CR, et al. A Randomized, Double-Blind, Placebo Controlled Trial to Assess the Effectiveness and Safety of Melatonin and Three Formulations of Floraworks Proprietary TruCBN\u2122 for Improving Sleep. medRxiv. 2023:2023.11.07.23298230.","DOI":"10.1101\/2023.11.07.23298230"},{"key":"1564_CR47","doi-asserted-by":"crossref","unstructured":"Kolobaric A, Hewlings SJ, Bryant C, Colwell CS, C RDA, Rosner B, et al. A Randomized, Double-Blind, Placebo-Controlled Decentralized Trial to Assess Sleep, Health Outcomes, and Overall Well-Being in Healthy Adults Reporting Disturbed Sleep, Taking a Melatonin-Free Supplement. Nutrients. 2023;15(17).","DOI":"10.3390\/nu15173788"},{"key":"1564_CR48","doi-asserted-by":"crossref","unstructured":"Emerson C, Webster C, Daza EJ, Klamer B, Tummalacherla M. Effect of cannabigerol on sleep and quality of life in Veterans: A decentralized, randomized, placebo-controlled trial2023.","DOI":"10.1101\/2023.08.31.23294611"},{"issue":"1","key":"1564_CR49","first-page":"12","volume":"3","author":"W Gannon","year":"2021","unstructured":"Gannon W, Bronfein W, Jackson D, Holshouser K, Farrakhan T, Artman B, et al. Novel Formulation of THC and CBN in a Repeat-Action Tablet Improves Objective and Subjective Measurements of Sleep. Am J Endocannabinoid Med. 2021;3(1):12\u20138.","journal-title":"Am J Endocannabinoid Med"},{"issue":"1","key":"1564_CR50","first-page":"215","volume":"1","author":"JL Saleska","year":"2022","unstructured":"Saleska JL, Pauli EK, Rezvan P, Cobb O, Chen J, Thorogood P, et al. The Safety and Effectiveness of Commercially Available Cannabidiol Products for Health and Well-Being: A Randomized, Multi-Arm. Open-Label Waitlist-Control Trial Integr Med Rep. 2022;1(1):215\u201326.","journal-title":"Open-Label Waitlist-Control Trial Integr Med Rep"},{"issue":"1","key":"1564_CR51","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12888-022-03948-6","volume":"22","author":"N Kuhathasan","year":"2022","unstructured":"Kuhathasan N, Minuzzi L, MacKillop J, Frey BN. An investigation of cannabis use for insomnia in depression and anxiety in a naturalistic sample. BMC Psychiatry. 2022;22(1):303.","journal-title":"BMC Psychiatry"},{"issue":"1","key":"1564_CR52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/npr2.12407","volume":"44","author":"M Murphy","year":"2024","unstructured":"Murphy M, Erridge S, Holvey C, Coomber R, Rucker JJ, Sodergren MH. A cohort study comparing the effects of medical cannabis for anxiety patients with and without comorbid sleep disturbance. Neuropsychopharmacol Rep. 2024;44(1):129\u201342.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"4","key":"1564_CR53","first-page":"186","volume":"14","author":"R Kaufmann","year":"2021","unstructured":"Kaufmann R. Use of a water-soluble form of cannabinol for the treatment of sleeplessness. Int J Complement Altern Med. 2021;14(4):186\u201390.","journal-title":"Int J Complement Altern Med"},{"issue":"7","key":"1564_CR54","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.5664\/jcsm.10528","volume":"19","author":"L Messineo","year":"2023","unstructured":"Messineo L, Norman D, Ojile J. The combination of atomoxetine and dronabinol for the treatment of obstructive sleep apnea: a dose-escalating, open-label trial. J Clin Sleep Med. 2023;19(7):1183\u201390.","journal-title":"J Clin Sleep Med"},{"key":"1564_CR55","doi-asserted-by":"crossref","unstructured":"Thomson L, Rankin T, Mehra S, Naughton M, Roebuck T, McDermott E, et al. 0451 Dronabinol Plus Acetazolamide for the Treatment of Obstructive Sleep Apnoea: A Proof of Concept and Mechanistic Exploration Study. Sleep. 2023;46(Supplement_1):A200-A1.","DOI":"10.1093\/sleep\/zsad077.0451"},{"key":"1564_CR56","doi-asserted-by":"crossref","unstructured":"Walsh J, Thomson L, Rankin T, Mehra S, Naughton M, Roebuck T, et al. 0451 Dronabinol Plus Acetazolamide for the Treatment of Obstructive Sleep Apnoea: A Proof of Concept and Mechanistic Exploration Study. Sleep. 2023;46(Supplement_1):A200-A1.","DOI":"10.1093\/sleep\/zsad077.0451"},{"issue":"SUPPL 1","key":"1564_CR57","doi-asserted-by":"publisher","first-page":"A259","DOI":"10.1093\/sleep\/zsaa056.675","volume":"43","author":"G Yin","year":"2020","unstructured":"Yin G, Reid K, Carley D, Prasad B, Zee P. Effects of cannabimimetic enhancement on subjective sleep quality and function in obstructive sleep apnea. Sleep. 2020;43(SUPPL 1):A259.","journal-title":"Sleep"},{"key":"1564_CR58","doi-asserted-by":"crossref","unstructured":"Carley DW, Prasad B, Reid KJ, Malkani R, Attarian H, Abbott SM, et al. Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea. Sleep. 2018;41(1).","DOI":"10.1093\/sleep\/zsx184"},{"issue":"7","key":"1564_CR59","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.28577","volume":"36","author":"C de Almeida","year":"2021","unstructured":"de Almeida C, Brito M, Bosaipo N, Pimentel A, Tumas V, Zuardi A, et al. Cannabidiol for Rapid Eye Movement Sleep Behavior Disorder. Mov Disord. 2021;36(7):1711\u20135.","journal-title":"Mov Disord"},{"issue":"2","key":"1564_CR60","first-page":"374","volume":"8","author":"CMO de Almeida","year":"2023","unstructured":"de Almeida CMO, Brito MMC, Bosaipo NB, Pimentel AV, Sobreira-Neto MA, Tumas V, et al. The Effect of Cannabidiol for Restless Legs Syndrome\/Willis-Ekbom Disease in Parkinson\u2019s Disease Patients with REM Sleep Behavior Disorder: A Post Hoc Exploratory Analysis of Phase 2\/3 Clinical Trial. Cannabis Cannabinoid Res. 2023;8(2):374\u20138.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"2","key":"1564_CR61","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jsmc.2022.03.003","volume":"17","author":"CM Morin","year":"2022","unstructured":"Morin CM, Jarrin DC. Epidemiology of Insomnia: Prevalence, Course, Risk Factors, and Public Health Burden. Sleep Med Clin. 2022;17(2):173\u201391.","journal-title":"Sleep Med Clin"},{"issue":"6","key":"1564_CR62","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s11606-018-4390-1","volume":"33","author":"E Koffel","year":"2018","unstructured":"Koffel E, Bramoweth AD, Ulmer CS. Increasing access to and utilization of cognitive behavioral therapy for insomnia (CBT-I): a narrative review. J Gen Intern Med. 2018;33(6):955\u201362.","journal-title":"J Gen Intern Med"},{"key":"1564_CR63","doi-asserted-by":"publisher","first-page":"101208","DOI":"10.1016\/j.smrv.2019.08.002","volume":"48","author":"T van der Zweerde","year":"2019","unstructured":"van der Zweerde T, Bisdounis L, Kyle SD, Lancee J, van Straten A. Cognitive behavioral therapy for insomnia: A meta-analysis of long-term effects in controlled studies. Sleep Med Rev. 2019;48:101208.","journal-title":"Sleep Med Rev"},{"key":"1564_CR64","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.sleep.2020.08.020","volume":"75","author":"HL Soh","year":"2020","unstructured":"Soh HL, Ho RC, Ho CS, Tam WW. Efficacy of digital cognitive behavioural therapy for insomnia: a meta-analysis of randomised controlled trials. Sleep Med. 2020;75:315\u201325.","journal-title":"Sleep Med"},{"key":"1564_CR65","doi-asserted-by":"publisher","first-page":"417S","DOI":"10.1002\/j.1552-4604.1981.tb02622.x","volume":"21","author":"E Carlini","year":"1981","unstructured":"Carlini E, Cunha J. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981;21:417S-S427.","journal-title":"J Clin Pharmacol"},{"key":"1564_CR66","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/BF00437513","volume":"33","author":"D Cousens","year":"1973","unstructured":"Cousens D, DiMascio A. THC as an Hypnotic: An experimental study of three dose levels. Psychopharmacologia. 1973;33:355\u201364.","journal-title":"Psychopharmacologia"},{"issue":"2","key":"1564_CR67","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","volume":"110","author":"MA Ware","year":"2010","unstructured":"Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604\u201310.","journal-title":"Anesth Analg"},{"issue":"10","key":"1564_CR68","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","volume":"239","author":"M Butler","year":"2022","unstructured":"Butler M, Jelen L, Rucker J. Expectancy in placebo-controlled trials of psychedelics: if so, so what? Psychopharmacology. 2022;239(10):3047\u201355.","journal-title":"Psychopharmacology"},{"key":"1564_CR69","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.sleep.2019.12.002","volume":"66","author":"T Andrillon","year":"2020","unstructured":"Andrillon T, Solelhac G, Bouchequet P, Romano F, Le Brun MP, Brigham M, et al. Revisiting the value of polysomnographic data in insomnia: more than meets the eye. Sleep Med. 2020;66:184\u2013200.","journal-title":"Sleep Med"},{"issue":"6","key":"1564_CR70","doi-asserted-by":"publisher","first-page":"e14036","DOI":"10.1111\/jsr.14036","volume":"32","author":"L Frase","year":"2023","unstructured":"Frase L, Nissen C, Spiegelhalder K, Feige B. The importance and limitations of polysomnography in insomnia disorder-a critical appraisal. J Sleep Res. 2023;32(6):e14036.","journal-title":"J Sleep Res"},{"issue":"1","key":"1564_CR71","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/cts.13425","volume":"16","author":"JC Arnold","year":"2023","unstructured":"Arnold JC, McCartney D, Suraev A, McGregor IS. The safety and efficacy of low oral doses of cannabidiol: An evaluation of the evidence. Clin Transl Sci. 2023;16(1):10\u201330.","journal-title":"Clin Transl Sci"},{"key":"1564_CR72","doi-asserted-by":"crossref","unstructured":"Perez-Reyes M, Timmons M, Davis K, Wall E, =. Pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol. Experientia. 1973;29(11):1368\u20139.","DOI":"10.1007\/BF01922823"},{"key":"1564_CR73","doi-asserted-by":"crossref","unstructured":"Longo MC, Hunter CE, Lokan RJ, White JM, & , White MA. The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part ii: the relationship between drug prevalence and drug concentration, and driver culpability. Accident; analysis and prevention. 2000;32(5):623\u201333.","DOI":"10.1016\/S0001-4575(99)00110-4"},{"key":"1564_CR74","doi-asserted-by":"crossref","unstructured":"Gedin F, Blom\u00e9 S, Pont\u00e9n M, Lalouni M, Fust J, Raquette A, et al. Placebo Response and Media Attention in Randomized Clinical Trials Assessing Cannabis-Based Therapies for Pain: A Systematic Review and Meta-analysis. JAMA Network Open. 2022;5(11):e2243848-e.","DOI":"10.1001\/jamanetworkopen.2022.43848"},{"issue":"1","key":"1564_CR75","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/08897077.2015.1023484","volume":"37","author":"P Gates","year":"2016","unstructured":"Gates P, Albertella L, Copeland J. Cannabis withdrawal and sleep: A systematic review of human studies. Substance Abuse. 2016;37(1):255\u201369.","journal-title":"Substance Abuse"},{"key":"1564_CR76","doi-asserted-by":"crossref","unstructured":"Emerson CR, Webster CE, Daza EJ, Klamer BG, Tummalacherla M. Effect of cannabigerol on sleep and quality of life in Veterans: A decentralized, randomized, placebo-controlled trial. medRxiv. 2023:2023.08.31.23294611.","DOI":"10.1101\/2023.08.31.23294611"},{"issue":"12","key":"1564_CR77","doi-asserted-by":"publisher","first-page":"e0189614","DOI":"10.1371\/journal.pone.0189614","volume":"12","author":"AR Jacobsen","year":"2017","unstructured":"Jacobsen AR, Eriksen F, Hansen RW, Erlandsen M, Thorup L, Damg\u00e5rd MB, et al. Determinants for adherence to continuous positive airway pressure therapy in obstructive sleep apnea. PLoS ONE. 2017;12(12):e0189614.","journal-title":"PLoS ONE"},{"key":"1564_CR78","doi-asserted-by":"crossref","unstructured":"Calik MW, Carley DW. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats. Sleep. 2017;40(9).","DOI":"10.1093\/sleep\/zsx112"},{"key":"1564_CR79","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.resp.2013.10.001","volume":"190","author":"MW Calik","year":"2014","unstructured":"Calik MW, Radulovacki M, Carley DW. Intranodose ganglion injections of dronabinol attenuate serotonin-induced apnea in Sprague-Dawley rat. Respir Physiol Neurobiol. 2014;190:20\u20134.","journal-title":"Respir Physiol Neurobiol"},{"issue":"1\u20132","key":"1564_CR80","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.resp.2008.06.021","volume":"164","author":"DW Carley","year":"2008","unstructured":"Carley DW, Radulovacki M. Pharmacology of vagal afferent influences on disordered breathing during sleep. Respir Physiol Neurobiol. 2008;164(1\u20132):197\u2013203.","journal-title":"Respir Physiol Neurobiol"},{"issue":"6","key":"1564_CR81","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.5664\/jcsm.9116","volume":"17","author":"YN Ni","year":"2021","unstructured":"Ni YN, Yang H, Thomas RJ. The role of acetazolamide in sleep apnea at sea level: a systematic review and meta-analysis. J Clin Sleep Med. 2021;17(6):1295\u2013304.","journal-title":"J Clin Sleep Med"},{"issue":"6","key":"1564_CR82","doi-asserted-by":"publisher","first-page":"345","DOI":"10.31128\/AJGP-02-21-5845","volume":"50","author":"JC Arnold","year":"2021","unstructured":"Arnold JC. A primer on medicinal cannabis safety and potential adverse effects. Royal Aust Coll Gen Pract. 2021;50(6):345\u201350.","journal-title":"Royal Aust Coll Gen Pract"},{"key":"1564_CR83","doi-asserted-by":"crossref","unstructured":"Anderson LL, Doohan PT, Oldfield L, Kevin RC, Arnold JC, Berger M, et al. Citalopram and Cannabidiol: In Vitro and In Vivo Evidence of Pharmacokinetic Interactions Relevant to the Treatment of Anxiety Disorders in Young People. J Clin Psychopharmacol. 2021;41(5):523\u201333.","DOI":"10.1097\/JCP.0000000000001427"},{"key":"1564_CR84","doi-asserted-by":"crossref","unstructured":"Rosen IM, Ramar K, Chervin RS, Carden KA, Aurora RN, Kristo D, et al. American Academy of Sleep Medicine Board of Directors. Medical cannabis and the treatment of obstructive sleep apnea: an American Academy of Sleep Medicine position statement. J Clin Sleep Med. 2018;14(4):679\u201381.","DOI":"10.5664\/jcsm.7070"},{"issue":"5","key":"1564_CR85","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/jcpt.12179","volume":"39","author":"MH Chagas","year":"2014","unstructured":"Chagas MH, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson\u2019s disease patients: a case series. J Clin Pharm Ther. 2014;39(5):564\u20136.","journal-title":"J Clin Pharm Ther"},{"issue":"4","key":"1564_CR86","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1089\/can.2019.0068","volume":"5","author":"MA Leehey","year":"2020","unstructured":"Leehey MA, Liu Y, Hart F, Epstein C, Cook M, Sillau S, et al. Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label. Dose-Escalation Study Cannabis Cannabinoid Res. 2020;5(4):326\u201336.","journal-title":"Dose-Escalation Study Cannabis Cannabinoid Res"},{"key":"1564_CR87","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.sleep.2017.04.019","volume":"36","author":"T Megelin","year":"2017","unstructured":"Megelin T, Ghorayeb I. Cannabis for restless legs syndrome: a report of six patients. Sleep Med. 2017;36:182\u20133.","journal-title":"Sleep Med"},{"issue":"1","key":"1564_CR88","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s11325-019-01978-1","volume":"24","author":"I Ghorayeb","year":"2020","unstructured":"Ghorayeb I. More evidence of cannabis efficacy in restless legs syndrome. Sleep and Breathing. 2020;24(1):277\u20139.","journal-title":"Sleep and Breathing"},{"key":"1564_CR89","unstructured":"National RLS Opioid Registry 4-Year Data Update: What RLS Treatments are Registry Participants Using? [press release]. https:\/\/www.massgeneral.org\/assets\/mgh\/pdf\/rls-registry\/registry-update-10.pdf: Massachusetts General Hospital, Sleep Disorders Clin Res Prog. 2023."},{"key":"1564_CR90","doi-asserted-by":"crossref","unstructured":"Pivik R, Zarcone V, Dement W, Hollister L. Sleep during one week of administration of \u0394-9 tetrahydrocanabinol to psychiatric patients. Clin Pharmacol Ther. 1972;13(3).","DOI":"10.1002\/cpt1972133426"},{"issue":"4","key":"1564_CR91","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/cpt1975174458","volume":"17","author":"I Feinberg","year":"1975","unstructured":"Feinberg I, Jones R, Walker JM, Cavness C, March J. Effects of high dosage delta-9-tetrahydrocannabinol on sleep patterns in man. Clin Pharmacol Ther. 1975;17(4):458\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"1564_CR92","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/cpt1973143344","volume":"14","author":"MJ Hosko","year":"1973","unstructured":"Hosko MJ, Kochar MS, Wang RIH. Effects of orally administered delta-9-tetrahydrocannabinol in man. Clin Pharmacol Ther. 1973;14(3):344\u201352.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1564_CR93","first-page":"47","volume":"8","author":"E Barratt","year":"1974","unstructured":"Barratt E, Beaver W, White R. The effects of marijuana on human sleep patterns. Biol Psychiat. 1974;8(1):47\u201354.","journal-title":"Biol Psychiat"},{"key":"1564_CR94","doi-asserted-by":"publisher","first-page":"315","DOI":"10.3389\/fphar.2018.00315","volume":"9","author":"IMP Linares","year":"2018","unstructured":"Linares IMP, Guimaraes FS, Eckeli A, Crippa ACS, Zuardi AW, Souza JDS, et al. No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled. Crossover Study Front Pharmacol. 2018;9:315.","journal-title":"Crossover Study Front Pharmacol"},{"issue":"1","key":"1564_CR95","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/08897077.2015.1023484","volume":"37","author":"P Gates","year":"2016","unstructured":"Gates P, Albertella L, Copeland J. Cannabis withdrawal and sleep: A systematic review of human studies. Subst Abus. 2016;37(1):255\u201369.","journal-title":"Subst Abus"}],"updated-by":[{"DOI":"10.1007\/s11920-024-01580-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000}}],"container-title":["Current Psychiatry Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-024-01564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11920-024-01564-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11920-024-01564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T17:06:01Z","timestamp":1736269561000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11920-024-01564-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":95,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1564"],"URL":"https:\/\/doi.org\/10.1007\/s11920-024-01564-7","relation":{},"ISSN":["1523-3812","1535-1645"],"issn-type":[{"value":"1523-3812","type":"print"},{"value":"1535-1645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"3 November 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Isobel Lavender and Grace Garden should have been denoted as equally contributing first authors and in Table 2 footnote the legend \"T delta-9-tetrahydro-cannabinool\" should be \"THC delta-9-tetrahydrocannibinol.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2024","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s11920-024-01580-7","URL":"https:\/\/doi.org\/10.1007\/s11920-024-01580-7","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CMH is funded by a National Heart Foundation Future Leader Fellowship. RRG (1197439) is funded by a National Health and Medical Research Council-Australian (NHMRC) Investigator Grant. IL was supported by a Barry and Joy Lambert Postgraduate Research Scholarship between 2021\u20132023.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial Disclosures"}},{"value":"RRG has received discounted investigational products from Neurim Pharmaceuticals and received investigational product and matched placebo from Teva Pharmaceutical in unrelated clinical trials. He has received funding for lectures for Pfizer, Teva, Jazz and Eisai in the past 3\u00a0years. RRG is a consultant for Eli Lilly. The other authors have no competing interests to disclose. The Woolcock Institute Sleep and Chronobiology Research Group has received research support from Avadel, Nyxoah, Idorsa, ResMed, BOD Australia, and Philips.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}